Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks ...
1 day ago · Bad news for Eli Lilly (LLY-6.59%) stock dragged down shares of rival companies in the market for GLP-1 diet drugs on Tuesday. ... Archrival Novo Nordisk (NVO-4.07%) is down 3.3% in sympathy, ...
Novo Nordisk’s next-generation weight-loss drug CagriSema ...
Dec 20, 2024 · Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently approved medicine, Zepbound, but didn’t cleanly surpass it in...
Novo Nordisk shares plunge 20% after disappointing trial ...
Dec 20, 2024 · Shares of Danish pharmaceutical giant Novo Nordisk plummeted more than 24% at one point Friday after reporting trial results that missed expectations.
Latest news - Novo Nordisk
Dec 18, 2024 · We plan to invest 2.9 billion Danish kroner to establish a cutting-edge quality control laboratory in Hillerød, Denmark. Environmental challenges have never been more critical or more urgent than they are today. But at Novo Nordisk, we never allow complexity to become a barrier to change.
Why Novo Nordisk Stock Got Destroyed Today, but Eli Lilly and ...
Dec 20, 2024 · Novo Nordisk reported disappointing clinical trial results for its CagriSema weight loss drug today. Novo investors are sad, but investors in Eli Lilly and Viking Therapeutics are glad....
Company announcements & press releases - Novo Nordisk
Product-related press releases will only be available upon request after three weeks of publication on our website in order to comply with applicable regulation.
Novo Nordisk Sinks on Disappointing Trial Results for Next ...
Dec 20, 2024 · Novo Nordisk's (NVO) U.S.-listed shares sank over 19% in premarket trading Friday after releasing trial results for its next generation of weight loss drug, meant to add to its current lineup of...
Novo Nordisk shares plunge after CagriSema obesity drug trial ...
Dec 20, 2024 · LONDON/COPENHAGEN (Reuters) -Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125...
Compounded semaglutide associated with at least 10 deaths ...
Nov 6, 2024 · Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have been associated with at least 100 hospitalizations and 10 deaths, the chief...
News Details - novonordisk.com
Jan 8, 2025 · Novo Nordisk Media: Ambre James-Brown +45 3079 9289 [email protected]: Liz Skrbkova (US) +1 609 917 0632 [email protected]: Novo Nordisk investors: Jacob Martin Wiborg Rode +45 3075 5956 [email protected]: David Heiberg Landsted +45 3077 6915 [email protected]: Sina Meyer +45 3075 6656 [email protected]: Ida Schaap Melvold +45 ...
- Some results have been removed